Zymeworks (ZYME) Current Leases (2021 - 2026)
Zymeworks (ZYME) posted Current Leases of $3.3 million for Q1 2026, down 5.53% sequentially from $3.5 million in Q4 2025, and up 0.64% YoY from $3.3 million in Q1 2025.
Analysis
Zymeworks (ZYME) Current Leases (2021 - 2026) Analysis & Trends
Zymeworks has reported Current Leases for 6 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Current Leases rose 0.64% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 0.64% YoY) and the FY2025 annual result came in at $3.5 million, up 26.68% from the prior year.
- Current Leases retreated to $3.3 million in Q1 2026 per ZYME's latest filing, from $3.5 million in the prior quarter.
- Over five years, Current Leases peaked at $4.6 million in Q3 2022 and troughed at $2.7 million in Q4 2024.
- A 5-year average of $3.5 million and a median of $3.4 million in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2024: Current Leases soared 153.59% in 2022, then sank 35.7% in 2024.
- Over 5 years, Current Leases stood at $3.3 million in 2022, then advanced by 28.27% to $4.3 million in 2023, then plunged by 35.7% to $2.7 million in 2024, then rose by 26.68% to $3.5 million in 2025, then slipped by 5.53% to $3.3 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $3.3 million, $3.5 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 3.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.30 Mn |
| Mar 31, 2026 | 3.28 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 3.26 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 2.84 Mn |
| Mar 31, 2024 | 4.16 Mn |
| Dec 31, 2023 | 4.26 Mn |
| Sep 30, 2023 | 3.84 Mn |
| Jun 30, 2023 | 3.65 Mn |
| Mar 31, 2023 | 3.37 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Dec 31, 2021 | 1.31 Mn |